FDA Authorizes Hovilpri for Certain Refractory HSV Lesions

The U.S. Food and Drug Administration has granted approval for pritelivir (Hovilpri) to treat mucocutaneous lesions caused by herpes simplex virus (HSV) infection. This new authorization specifically targets certain patients with refractory HSV, offering a new therapeutic option for individuals who have not responded to existing treatments. The approval expands the available arsenal against challenging viral infections.